BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/10/2014 4:18:00 PM | Browse: 153 | Download: 199
Publication Name World Journal of Hepatology
Manuscript ID 2977
Country of Manuscript Source China
Received
2013-03-29 12:30
Peer-Review Started
2013-03-29 14:51
To Make the First Decision
2013-04-16 09:16
Return for Revision
2013-04-18 19:38
Revised
2013-04-26 13:12
Second Decision
2013-06-08 14:12
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-06-10 04:11
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-06-21 13:21
Typeset the Manuscript
2013-07-19 17:18
Publish the Manuscript Online
2013-07-25 09:10
ISSN 1948-5182 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Review
Article Title Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Bo Zhai and Xue-Ying Sun
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Scientific Foundation of China 30973474
National Natural Scientific Foundation of China 81272467
Correspondence To Xue-Ying Sun, MD, PhD, Professor, The Hepatosplenic Surgery Center, Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China. kevsun88@hotmail.com
Keywords Hepatocellular carcinoma; Sorafenib; Drug resistance; Cellular signaling pathway; Clinical trials
Core Tip The primary resistance of hepatocellular carcinoma (HCC) to sorafenib is due to genetic heterogeneity. Thus, seeking predictive biomarkers and combining sorafenib with other anticancer agents for HCC have been launched with varying degrees of success. Sorafenib inhibits several kinase targets but it can also simultaneously or sequentially activate the addiction switches and compensatory pathways, inducing acquired resistance. Some other molecular targeted drugs have been used as second-line treatment for advanced HCC after the failure of sorafenib therapy. Further investigation on the crosstalk and relationship of associated pathways will better our understanding of the mechanisms accounting for sorafenib resistance in HCC.
Publish Date 2013-07-25 09:10
Citation Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J Hepatol 2013; 5(7): 345-352
Url http://www.wjgnet.com/1948-5182/full/v5/i7/345.htm
DOI http://dx.doi.org/10.4254/wjh.v5.i7.345
Full Article (PDF) WJH-5-345.pdf
Revised Manuscript 2977-Review.docx
Peer-review Report 2977-Peer review(s).pdf
Answering Reviewers 2977-Answering reviewers.docx
Scientific Editor Work List 2977-Scientific editor work list.doc
Copyright Assignment 2977-Copyright assignment.PDF